Belite Bio (BLTE) Debt Ratio (2021)

Belite Bio's (BLTE) quarterly Debt Ratio came in at 0.0 in Q4 2021.

Belite Bio (BLTE) Debt Ratio (2021) Analysis & Trends

Belite Bio's Debt Ratio history runs 1 years deep, the most recent figure standing at 0.0 for Q4 2021.

On a quarterly basis, Debt Ratio changed N/A year-over-year to 0.0 in Q4 2021; TTM through Dec 2021 was 0.0, a N/A change from a year earlier, with the FY2021 full-year figure at 0.0, changed N/A from the prior year.
Debt Ratio steadied at 0.0 in Q4 2021 per BLTE's latest filing.
Across five years, Debt Ratio topped out at 0.0 in Q4 2021 and bottomed at 0.0 in Q4 2021.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-	1.41
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn	0.11
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn	0.05
7	Belite Bio	61.40 Bn	61.40 Bn	-	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn	-
9	Revolution Medicines	37.37 Bn	37.37 Bn	-	-
10	Alnylam Pharmaceuticals	36.08 Bn	33.07 Bn	959.66 Mn	-

Historic Data

Download Data

Date	Value
Dec 31, 2021	0.00